Clinical Trial Update: Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports Phase 1/2 results for Enasidenib in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) without IDH2 mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• Enasidenib (Idhifa) (enasidenib)

Snippet

Sponsor: Tian Yi Zhang | Conditions: Leukemia, Leukemia, Myeloid | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-04-17